AltPep Corporation Announces Close of $53 Million Series B Financing to Advance Its Novel Therapeutics for both Alzheimer’s and Parkinson’s Diseases into the Clinic

“AltPep Corporation, a privately-held biotechnology company developing early disease-modifying treatments and detection tools for amyloid diseases, today announced the completion of a $52.9 million Series B financing round. The financing was led by Senator Investment Group, LP, with participation from new financial investors, Section 32, Korea-based Partners Investment, and Eli Lilly and Company. Investors in AltPep’s Series A, including Alexandria Venture Investments and Matrix Capital Management Company, LP, also participated in the Series B.”

The Risk of AIRA

Amyloid plaque are targeted and mobilized by anti-amyloid antibodies (such as lecanamab and donanamab). The antibody-bound plaque clear through the brain’s immune cells, called microglia, by binding Fc-gamma Receptors (FCgRs). (Alzheimers Dis Rep. 2023) This binding alters the microglia resulting in inflammation and cytokine storm and thereby creating a high risk of ARIA (https://ajronline.org/doi/epdf/10.2214/AJR.22.28461).

Linkedin-in

Valerie Daggett, PhD

Chief Executive Officer

Valerie, the CEO/Founder of AltPep and an Endowed Professor of Bioengineering at the University of Washington, has been a champion of groundbreaking research for over 30 years. Her inherent curiosity pushes her to uncover new ways of tackling problems in the field of amyloid diseases, where successes are few.  Her tenacity led to a revolutionary discovery of a protein structure that could dramatically change the diagnosis and treatment of Alzheimer’s disease and over 50 other amyloid diseases. At AltPep, Valerie leads a team of innovators who are developing this platform to make the early, pre-symptomatic diagnosis and treatment of amyloid diseases a reality. Valerie holds a BA from Reed College, PhD from the University of California, San Francisco, and was a Postdoctoral Fellow at Stanford University.